DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 03:59:46 2024-05-29 am EDT | ||
| 349.94 EUR / 350.68 EUR | -0.55% |
|
| Current month | +3.56% | ||
| 1 month | +3.94% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 352.2 | -0.09% |
| 24-05-27 | 352.6 | +0.12% |
| 24-05-24 | 352.1 | -0.14% |
| 24-05-23 | 352.6 | +0.28% |
| 24-05-22 | 351.7 | +0.61% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 04:47 am EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7D8R |
| ISIN | DE000ME7D8R8 |
| Date issued | 2024-01-23 |
| Maturity | 2024-12-20 (206 Days) |
| Parity | 1 : 1 |
| Emission price | 337 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 352.6 € |
|---|---|
| Lowest since issue | 328.6 € |
| Spread | 1.37 € |
| Spread % | 0.39% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
446.9
USD
Average target price
462.8
USD
Spread / Average Target
+3.57%
- Stock Market
- Certificates
- Certificat
